International Journal of Inflammation, Cancer and Integrative Therapy

Case Study Open Access

Advances in mRNA Nanomedicines for the Treatment of Malignant Brain Tumours

Banzhou Zang*

Department of Oncology, People's Hospital of Shenzhen Baoan District, The Second Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, 518055, China

Abstract

Currently, nasty brain excrescences are still substantially murderous conditions with poor prognostic and a clinical standard survival rate of smaller than 2 times after remedial intervention. It's delicate to achieve complete absolution of brain excrescences due to blood-brain hedge (BBB) and a lack of effective medicine delivery systems to targeted transportation of brain excrescence drugs [1]. Nanoparticle delivery systems have shown graces including stability and high carrier capacity for the transportation of different medicines to treat brain excrescences. The operation of mRNA nanomedicines brings in great pledge not only in COVID-19, but also for nasty brain excrescence immunotherapy. The applicable delivery system facilitates mRNA delivery effectiveness and enhances the vulnerable response successfully, for optimal treatment issues on nasty brain excrescences [2]. Herein, we do an streamlined review on the development of mRNA nanomedicines for nasty brain cancer treatment. We concentrate on how to design mRNA-loaded nanoparticle-grounded delivery systems with optimized pharmacokinetics and pharmacodynamics for effective remedy of brain cancers. In addition, we point out the challenges and results for farther development of mRNA nanomedicines for brain cancer remedy. We hope this review would stimulate interest among experimenters with different backgrounds and expedite the restatement from bench to bedside for the mRNA nanomedicines [3].

Keywords: Brain tumor; mRNA nanomedicines; Nanoparticles; Drug delivery; Therapy

Introduction

Nasty brain cancer is one of the most intractable cancers with mortality rates staying unchanged over the once 30 times, though new treatment approaches are arising. Especially for children and adolescents, brain cancer is the leading cause of all pediatric cancer-related death. 75 of primary brain cancer is gliomas, neuroectodermal excrescences origin from glial or precursor cells and include astrocytomas, oligodendrogliomas, and ependymomas, neuroectodermal [4]. In clinic, the glioma is primarily divided into pilocytic astrocytoma, verbose low-grade gliomas, verbose high-grade gliomas and glioblastoma according to the WHO bracket. piecemeal from primary brain cancer, utmost nasty brain cancers are metastatic brain cancer. It's estimated that 30 chance of cases with nasty primary cancer will develop into brain metastases, similar as lung excrescence and colorectal excrescence still, the nasty brain excrescence development can damage the integrity of the BBB and form blood excrescence hedge (BTB) [5]. Accumulating attestations gradationally reveal that the BTB is characterized by miscellaneous permeability, reduced integrity, loss of astrocytic endfeet connections and enhanced permeability. Significantly, the BTB alters the molecular situations including downregulating endothelial proteins and receptor-intermediated transport pathways to enhance the paracellular permeability by downregulating the votaries and tight junction factors [6]. Also, numerous efflux transporters aren't observed in BTB, similar as ABCB1 and ABCG2. In addition, the structure of BTB is largely told by cancer cell colonization, vulnerable cell infiltration and the neuroinflammatory response. Scientists have tried to overcome the limitation of BBB/ BTB with colorful results, including receptor agonists, liposome vectors, and nanoparticles. Thereinto, the transferrin-modified nanoparticle and transcytotic nanoparticle delivery show more prospective in prostrating the BBB. mRNA nanomedicines show tremendous remedial eventuality in complaint rectifiers, especially in contagious conditions, cancers. The outbreak of COVID-19 gives mRNA the applicable occasion for development [7] In 1990, Wolff et al. originally demonstrated that the injection of mRNA and DNA expression vector into mouse cadaverous muscle could directly induce the protein expression of targeted gene. Decreasingly, the burst of COVID-19 accelerated speed of development and application of mRNA nanomedicines. As one of the prevailing drugs, mRNA has egregious advantages in several aspects. originally, the mRNA can be restated into protein in cytoplasm without being integrated into DNA genome and reduce the threat of insertional mutagenesis therefore, the mRNA is more secure than other DNA-grounded insertions. Second, the mRNA is fully biodegradable in the cytoplasm the via metabolism pathway. In addition, the mRNA product is comparatively low-cost and simple in pharmaceutical product. Another RNA remedial antisense RNA (RNAi) also exhibits huge eventuality in cancer remedy [8]. The structure of in vitro transcribed mRNA is designed to act the natural mature mRNA which consists of a cap, the 5 ′ and 3 ′ untranslated regions (UTRs), an open reading frame (ORF) and a poly (A) tail. Except for the ORF, which plays main part in mRNA function as the protein rendering area, other regions are also necessary. The UTRs contribute to mRNA stability, mRNA localization, and translational effectiveness. The poly (A) tail protects the mRNA from declination. The mRNA nanomedicines development is extremely fast and flourishing, and accumulatedpre-clinic data and clinic trails indicates the great pledge of mRNA nanomedicines in cancer immunotherapy. In this review, we will describe the medium of BBB, the principles of mRNA nanomedicine design, current nanoparticles for delivery of mRNA in nasty brain excrescence, as well as the challenges of mRNA nanomedicines in nasty brain excrescence treatment [9].

***Corresponding author:** Banzhou Zang, Department of Oncology, People's Hospital of Shenzhen Baoan District, The Second Affiliated Hospital of Shenzhen University Shenzhen, Guangdong, China, E-mail: banzang@qq.com

Received: 25-Jan-2023, Manuscript No. ijm-23-89691; **Editor assigned:** 28-Jan-2023, PreQC No. ijm-23-89691; **Reviewed:** 11-Feb-2023, QC No. ijm-23-89691; **Revised:** 21-Feb-2023, Manuscript No. ijm-23-89691(R); **Published:** 28-Feb-2023, DOI: 10.4172/2381-8727.1000209

Citation: Zang B (2023) Advances in mRNA Nanomedicines for the Treatment of Malignant Brain Tumours. Int J Inflam Cancer Integr Ther, 10: 209.

Methods

BBB transportation

Mechanism of molecular BBB transportation

The patch transfer into BBB or BTB through multiple styles including unresistant verbose, endocytosis, carrier-intermediated transport, and active transport. Passive verbose is the process infrequently dependent on attention grade. The unresistant substantially depends on lipophilicity. Small lipophilic motes with molecular weight< 500 Da similar as glycerol, adipose acids, ethylene glycol verbose through cell membranes. piecemeal from unresistant prolixity, other transportation styles are energy dependent. The endocytosis is defined by large patch transportation by the tube membrane of the cell invaginates and forming a fund around the target patches. For large composites, similar proteins, pass through BBB via endocytosis by binding to particular receptor ornon-specific pathway including cationization and adsorptive-mediated transcytosis.

Carrier-intermediated transportation (CMT) is another important medium for nutrients and metabolites transport across the BBB. The CMT is dependent on BBB picky transporters, similar as hexose or monocarboxylate transporters, whose development number can be achieved around 270 – 3000 motes/ s. The active transport is dependent on ATP-list mail transporters (ABC transporters) expressed on the luminal and abluminal sides of blood vessel walls. Large hydrophobic medicines(> 500 Da), they're always dissuaded by the ABC transporter in case of crossing BBB. ABC transporters family is one of the largest and conceivably one of the oldest transport system superfamily families. They use the energy from ATP list and hydrolysis to load substrates across cellular membranes. To achieve largely effective medicine delivery to brain, numerous strategies were developed grounded on transporters on brain capillary endothelial cells [10].

According to the property, mRNA nanomedicines is divided into three categories. The first type is non-replicating mRNA. The natural non-replicative mRNA comprising a 5′ cap, a 5′-untranslated region (UTR), an ORF, a 3′-UTR, and a poly (A) tail encoding antigen. This mRNA nanomedicines are packaged and delivered into cells to produce antigens. The second is a self-replicating mRNA vaccine. Different from non-replicative mRNA, the self-replicating mRNA nanomedicines contains 5′cap, 5′-UTR, the sequence coding for nonstructural proteins (NSP), subgenomic promoter sequence, open reading frame, 3′-UTR, and a 3′ poly(A) tail. The third is in vitro dendritic cell non-replicating. The dendritic cells, extracted from the patient's blood, are transfected with RNA nanomedicines, then infusing back into patients to induce immune response.

The delivery process of mRNA

mRNA with a weight of 105 – 106 Da belongs to a biomacromolecule and induces an ineluctable vulnerable response. also, mRNA declination is current in vivo because of ubiquitous nucleases. likewise, the mRNA has a high negative charge as well as the bilayer phospholipid membrane. In addition, the naked mRNA doesn't have an effective target capability for the foci of complaint, thus, unlike other RNA rectifiers similar as Small snooping RNA (siRNA) and Antisense oligonucleotides (ASOs), which can be chemical revision and delivered using conjugates, the applicable carrier is necessary for mRNA-grounded medicines to get access to a target cell. The delivery strategy of mRNA can be astronomically classified into two distinct groups, videlicet viral andnon-viral grounded deliveries [11].

Viral-grounded delivery

The current delivery approach substantially focuses onnon-viral-based delivery systems similar as polymers and lipid nanoparticles (LNPs) still, the viral-grounded delivery system still has implicit operation prospects. The development of gene remedy brings great stopgap for multiple conditions, including cancer, and neurological diseases. The success of gene remedy requires an effective gene delivery system connecting targeted genes and lesions. For a complete delivery system, three core factors plasmid-grounded gene expression system, gene expression target protein and control part manipulate the whole delivery system. While current gene delivery system substantially contains viral andnon-viral delivery. Viral vectors have high transduction effectiveness, epichromosomal continuity, broad tropism and the vacuity of scalable product in practice. Current viral vectors for gene delivery includes retroviruses, adenoviruses (Advertisements) or adeno-associated contagions (AAVs) [12]. The Adeno-associated contagion (AAV) vectors, instanced by replication-imperfect, and nonenveloped, is leading in in vivo gene remedy. In structure, the recombinant AAV (rAAV) is composed of original reversed terminal reprises (ITRs) and remedial gene expression cassettes (containing a protagonist, a transgene and a recap termination signal). The first FDA-approved gene remedy is Luxturna manufactured by Spark rectifiers for cases are diagnosed with biallelic RPE65 mutation-associated retinal dystrophy. Following, multitudinous AAV clinical trials are underway, and the suggestions are substantially concentrated on Parkinson's complaint. Given the AAV capsids, the firstly finagled AAV2 serotype is most popular because of safety and efficacy. In utmost clinical trials for brain diseases, the viral vectors are constantly introduced to brain parenchyma via neurosurgical infusion or intracerebroventricular (ICV) or intrathecal (IT) injections to duck BBB. still, this system has distinct downsides including spatial restrictions and surgery-related side goods. Worsley, the physical injection still causes off-target goods as well as significant immunogenicity and toxin enterprises. Meanwhile, exogenous viral patches with immunogenicity threat converting a strong vulnerable response in vivo bringing about safety questions in clinic. Thenon-viral vector, generated by biocompatible accoutrements like lipids and polymers has low immunogenicity and cytotoxicity. In addition, thenon-viral vector is also characterized by high packaging capacity for remedial genes and face revision superiority in brain complaint remedy. Thenon-viral gene remedy includes physical and biomaterial styles [13]. The physical system is always conducted without gene vectors, similar as microinjection, electroporation, and magnetofection. The physical delivery system is simple with no redundant vector involved, but advanced surgical interventions are needed. In medicine delivery, the routine biomaterials comprise synthetic biodegradable polymers, and naturally being polymers. The delivery accoutrements must be biodegradable to insure anon-toxic effect on humans. For illustration, poly (lactic acid) (PLA) and the corresponding copolymer Poly lactic-co-glycolic acid (PLGA), and mortal serum albumin have biodegradation nature in mortal body.

Biodegradable accoutrements

The PLGA copolymerized by poly lactic acid (PLA) and polyglycolic acid (PGA), is the most popular biodegradable nanoparticle material applied in the delivery carrier for macromolecules delivery. Poly (lactic-co-glycolic acid) has been developed to control-lozenge release loadings. To ameliorate the gene lading and transfection effectiveness, the PLGA nanoparticles are modified with positive charges similar as biocompatible chitosan or other cationic factors. The PLGA NPs has capability to access through the BBB by different pathways active endocytosis mechanisms including adsorption-intermediated

transcytosis (AMT), receptor-intermediated transcytosis (RMT) and carrier-intermediated transport (CMT). Some cationic variations ameliorate the brain uptake of PLGA NPs by the AMT conception [14]. Amino acids, which can pass through the BBB endothelium, were employed to modify the PLGA NPs to realize CMT. Ying Yin et, al constructed a delivery vehicle system PLGA-lysoGM1/ DOX micelles to access into the BBB and achieve greatanti-glioma effect. In a study, conducted by Cui et, al, the PLGA nanoparticles were carpeted with erythrocyte membranes as well as binary-modified with DWSW and NGR peptide ligands showed significant eventuality for the treatment of brain glioma by steadily piercing through the BBB and BBTB and producing cytotoxic goods. numerous studies also carpeted PLGA NPs with transferrin to realize blood – brain hedge (BBB) penetration by endocytosis [15]. Another generally employed nanoparticle is Poly (alkyl cyanoacrylate) (PACA). PACA is primarily created as surgical cement. Owing to high medicine-lading capacity and biodegradability, it's extensively exploited as a medicine carrier. In reality, PACA has a high face to volume rate, which contributes to its high face area and in turn high lading capacity. In addition. also, scientists also set up that the PEBCA (A (poly (2-ethyl-butyl cyanoacrylate)) NPs modulated the vulnerable response to enhance the remedial effect. To enhance the piercing capacity of PACA into BBB, the cut is applied to modify the PACA to avoid macrophage uptake. The decoration ofanti-Aβ1 – 42 antibody with PACA observably recovered the mouse memory of Alzheimer's complaint mouse model. Although the operation of PACA is more extensively applied in solid excrescence clinic trials, the progress in brain excrescence treatment is slow [16].

Conclusion

This review has bandied several types of NP in mRNA nanomedicines delivery in brain cancer. The huge progress in delivery system promoted the mRNA nanomedicines development and restatement in viral infections and cancers. Especially, the mature LNP delivery system drives the commercialization of mRNA COVID-19 nanomedicines vaccine similar as BNT162b2 (Pfizer) and mRNA-1273 (Moderna), and brings huge benefits to mortal health. The success of mRNA nanomedicines brings broad anticipation in excrescence rectifiers. still, there are still numerous problems to overcome in the operation of mRNA nanomedicines in brain cancer. originally, the understanding of brain cancer biology is limited including the complex excrescence medium and effective TAA or TSA. Secondly, the delivery system development is trickier for brain cancer because of the BBB or BTB. numerous mRNA biotech companies similar as European Federation of Pharmaceutical diligence and Associations (EFPIA) have set the brain cancer channel. Although multiple nanoparticles accoutrements have been applied into medicine delivery in exploration, the lipid nanoparticle is more generally used in clinical exploration and operation. still, there are still some limitations in lipid nanoparticle originally, adding the cellular uptake and endosomal escape of lipid nanoparticles is still challenge. studies about the rational design of lipids by adaptation of head groups and hydrophobic tails, or mongrel nanoparticles in practical mRNA delivery are need to ameliorate delivery effectiveness. Different lipid type, size and face charge significantly impact the geste and biodistribution of lipid nanoparticles in vivo. Secondly, as reported, the lipid nanoparticle could induce hepatic damages in creatures. In addition to LNP, other nanoparticles that suitable in cancer also needs critical upgrade to promote mRNA nanomedicines. For exosome, the operation in clinic still has limitation in scalable product. In clinic, the critical precondition for introducing exosome into clinic is to establish standardized insulation styles to secure homogeneous and sufficient exosome While lack of standard product system impedes the operation of exosome in clinic. also, as a medicine carrier, the targeted revision also matters exosome carrier capability in mRNA delivery. The natural, chemical, and physical strategies modify exosome with targeting, but there are still some problems how to avoid the nonspecific targeting; how to maintain the low immunogenicity after revision. These directions still need further study and deep examinations to optimize the property of exosomes and other nanoparticles. In conclusion, the nanoparticles show great pledge in mRNA drug delivery and has huge eventuality in brain cancer operation.

Acknowledgement

None

Conflict of Interest

None

References

1. Chinot OL (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722.
2. Smith MA, Reaman GH (2015) Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatric Clinics 62: 301-312.
3. Lapointe S, Perry A, Butowski NA (2018) Primary brain tumours in adults. Lancet 392: 432-446.
4. Steeg PS (2021) The blood–tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol 18: 696-714.
5. Brastianos PK (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic TargetsGenomics of brain metastases. Cancer Discov 5: 1164-1177.
6. Wolff JA (1990) Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
7. Sahin U, Karikó K, Türeci O (2014) mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov 13: 759-780.
8. Bumcrot D, Manoharan M, Koteliansky V, Sah DW (2006)RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719.
9. Aagaard L, Rossi JJ (2007)RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59: 75-86.
10. Kim DH, Rossi JJ (2008)RNAi mechanisms and applications. Biotechniques 44: 613-616.
11. Tusup M (2019)Design of in vitro transcribed mRNA vectors for research and therapy. Chimia 73: 391-394.
12. Mauger DM (2019) mRNA structure regulates protein expression through changes in functional half-life. Proc Natl Acad Sci USA 116: 24075-24083.
13. Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT (2014) Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharmaceut Des 20: 1422-1449.
14. Sigismund S, Lanzetti L, Scita G, Di Fiore PP (2021)Endocytosis in the context-dependent regulation of individual and collective cell properties. Nat Rev Mol Cell Biol 22: 625-643.
15. Khan NU, Miao T, Ju X, Guo Q, Han L (2019) In brain targeted drug delivery system 129-158.
16. Puris E, Fricker G, Gynther M (2022) Targeting transporters for drug delivery to the brain: can we do better? Pharmaceut Res 1-41.